Radar technology is used to track vehicles, measure driving speeds, forecast weather changes and, now, to remotely monitor the severity and progression of Parkinson’s disease.

It doesn’t take a soothsayer to see what’s on the horizon for Seer Medical.

After launching their research-use-only test for monkeypox internationally this past July, BD and its Spain-based diagnostic partner CerTest Biotec are bringing their PCR assay to U.S. shores.

Neutrophils are the mercenaries of the immune system, but sometimes they’re messy fighters. The antimicrobial molecules they use as weapons don’t just knock out pathogens—in some cases, they damage healthy cells, too. When chronic or excessive, this activity is thought to be one of the mechanisms behind inflammatory conditions like sepsis, arthritis, atherosclerosis and some cancers, just to name a few.

Anebulo Pharmaceuticals is blazing through a phase 2 clinical trial of anti-cannabinoid intoxication drug candidate ANEB-001, delivering a fresh cut of data that suggests it can counter the effects of higher THC doses.

The botulinum toxin family of treatments may be best known for aesthetic applications like Botox, but companies have applied them more widely. In Aeon Biopharma’s case, its candidate ABP-450 hit its main goals in a phase 2 trial for a rare neck muscle disorder, setting the company up to launch a late-phase study next year.

Ferring Pharmaceuticals’ biotherapeutic passed an FDA committee vote despite some skepticism from a handful of members, setting up the asset for potential approval to treat Clostridioides difficile infection.

Though drugs can help treat many cases of epilepsy, for the roughly 30% of patients with drug-resistant cases, it can take decades to find an effective alternative.

After an almost yearlong wait, Spectrum Pharmaceuticals has received a pretty clear hint about whether the FDA will approve its lung cancer drug. Unfortunately, it’s unlikely to be the answer the company wants.

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain.